Clinical trials: Tuberculosis Treatment Effectiveness
Pulmonary Tuberculosis
TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis
Primary Objective: To compare, at the completion of the follow-up phase, the clinical and bacteriologic relapse rates associated with the two study regimens.
- Trial name
- NCT00023335
- Testing
- Rifapentine, Isoniazid
- Where
- 23 sites in United States, Canada
- Volunteers
- 1,000 people
- Sponsor
- Centers for Disease Control and Prevention
Tuberculosis
Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients.
The purpose of the study is to evaluate the efficacy and safety of Mycobacterium w in new lung tuberculosis patients. Mycobacterium w is a strain of bacterium which is being used as vaccine and adjunct drug against leprosy.
- Trial name
- NCT00341328
- Testing
- Intradermal injection of Mycobacterium w
- Where
- 2 sites in India
- Volunteers
- 300 people
- Sponsor
- Ministry of Science and Technology, India
Tuberculosis, Human Immunodeficiency Virus Infections
Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment
Protocol Summary Title: Evaluation of safety and efficacy of two different once daily anti-retroviral treatment regimens along with anti-tuberculosis treatment in patients with HIV-1 and tuberculosis - Randomized Controlled…
- Trial name
- NCT00332306
- Testing
- Didanosine, Lamivudine, Efavirenz, Didanosine, Lamivudine, Nevirapine
- Where
- India
- Volunteers
- 180 people
- Sponsor
- Tuberculosis Research Centre, India
Tuberculosis, Pleural Effusion
Efficacy Study of Thrice Weekly Directly Observed Treatment Short-Course Regimen in Tubercular Pleural Effusion
Tubercular pleural effusion is the second most common form of extrapulmonary tuberculosis (EPTB) seen in clinical practice after tuberculosis (TB) lymphadenitis.
- Trial name
- NCT01560078
- Where
- India
- Volunteers
- 360 people
- Sponsor
- All India Institute of Medical Sciences
Non-tuberculous Mycobacterial Infections
Linezolid for Treatment of Nontuberculous Mycobacterial Diseases
A prospective open study to determine the efficacy and tolerability of oral linezolid 600mg./day for the treatment of 40 patients with nontuberculous mycobacterial diseases will be conducted at Siriraj Hospital, Mahidol…
- Trial name
- NCT03220074
- Testing
- Oral Tablet
- Where
- Thailand
- Volunteers
- 40 people
- Sponsor
- Mahidol University
Nontuberculous Mycobacterial Infections
Effectiveness of Rifabutin in the Treatment of Mycobacterium Avium Complex
Treatment of adults with chronic Mycobacterium avium-intracellulare complex lung infections who have failed or are intolerant of rifampin.
- Trial name
- NCT03164291
- Testing
- Rifabutin
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- The University of Texas Health Science Center at Tyler
Tuberculosis
Effectiveness Of Mobile Application To Improve Adherence To Tuberculosis Treatment
Tuberculosis (TB) is a major public health concern, where it is among the top ten causes of death and the leading cause of death due to a single infectious agent globally.
- Trial name
- NCT05259254
- Testing
- Mobile Application, Direct Observed Therapy
- Where
- Malaysia
- Volunteers
- 300 people
- Sponsor
- Mohd Fazeli bin Sazali
Tuberculosis, Pulmonary
Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Therapy for Pulmonary Tuberculosis
New approaches are needed to achieve more rapid elimination of dormant mycobacteria and thereby shorten treatment for drug-sensitive and drug-resistant tuberculosis (TB).
- Trial name
- NCT01638520
- Testing
- Pascolizumab
- Where
- 7 sites in Malaysia, Philippines and 1 more
- Volunteers
- 32 people
- Sponsor
- National University Hospital, Singapore
Tuberculosis
Feasibility and Effectiveness of Community Based Isoniazid Preventive Therapy in Kenya
Isoniazid preventive therapy (IPT) is a well studied clinical intervention for primary and secondary prevention of active tuberculosis (TB) after infection with Mycobacterium tuberculosis.
- Trial name
- IPT (NCT00850915)
- Testing
- community IPT
- Where
- 18 sites in Kenya
- Volunteers
- 1,259 people, healthy volunteers welcome
- Sponsor
- KNCV Tuberculosis Foundation
Tuberculosis
Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients
The purpose of the study is to study the efficacy and safety of Mycobacterium in treating patients with lung tuberculosis . Mycobacterium is a strain of bacterium which is used as a vaccine and an adjuvant drug against leprosy.
- Trial name
- NCT00265226
- Testing
- Intra-dermal administration of Mycobacterium w
- Where
- 8 sites in India
- Volunteers
- 1,020 people
- Sponsor
- Ministry of Science and Technology, India
Pulmonary Tuberculosis
Study on the Use of Interferon Gamma (Ingaron) Injections in Patients With Drug-resistant Pulmonary Tuberculosis
The purpose of this study is to evaluate the efficacy and tolerability of the complex therapy of drug-resistant respiratory tuberculosis using the drug Ingaron, a lyophilisate for the preparation of a solution for injection for…
- Trial name
- NCT05359315
- Testing
- Interferon-Gamma
- Where
- Russia
- Volunteers
- 84 people
- Sponsor
- SPP Pharmaclon Ltd.
Tuberculosis (TB)
Pharmacist-led Digital Interventions to Improve Tuberculosis Treatment Adherence
The gold standard for tuberculosis (TB) treatment support requires directly observed therapy (DOT), which means a trained health worker observes the patient swallow each dose of medication every day for 2 months.
- Trial name
- CARE-TB (NCT07069387)
- Testing
- CARE-TB digital adherence package, Standard Care
- Where
- Malaysia
- Volunteers
- 81 people
- Sponsor
- University of Malaya
Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant
Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients
To evaluate the efficacy, safety and tolerability at 8 weeks (2-months), 52 weeks (12-months), and 104 Weeks (24-months) post the start of the following treatment regimens in participants with: Drug Sensitive TB (DS-TB) patients…
- Conditions
- Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR, Tuberculosis
- Trial name
- NCT03338621
- Testing
- Pretomanid, Bedaquiline, Moxifloxacin
- Where
- 26 sites in Brazil, Georgia and 6 more
- Volunteers
- 455 people
- Sponsor
- Global Alliance for TB Drug Development
Pulmonary TB
Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB
This trial will assess the safety and efficacy of OPC-167832 combined with delamanid and bedaquiline in participants with drug-susceptible tuberculosis (DS-TB) administered for 17 weeks compared to rifampin, isoniazid…
- Trial name
- NCT05221502
- Testing
- Delamanid, Bedaquiline, RHEZ
- Where
- 6 sites in South Africa
- Volunteers
- 122 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Tuberculosis (TB), Tuberculosis in Children
Shorter Treatment Regimen Implementation Evaluation Study
"Evaluation of the implementation of the shorter treatment regimen for children and adolescents with non-severe TB in Zambia" is a parallel and convergent mixed methods evaluation study of implementation and clinical outcomes of…
- Conditions
- Tuberculosis (TB), Tuberculosis in Children, Tuberculosis Treatment Effectiveness, Tuberculosis Active
- Trial name
- EvSTR (NCT07747792)
- Where
- Zambia
- Volunteers
- 175 people
- Sponsor
- Centre for Infectious Disease Research in Zambia
Latent Tuberculosis
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
This study is conducted to compare the safety and effectiveness of a novel short 6-week regimen of daily rifapentine (6wP, experimental arm) with a comparator arm of 12-16 weeks of rifamycin-based treatment (standard of care…
- Trial name
- ASTERoiD (NCT03474029)
- Testing
- Rifapentine daily for 6 weeks, Rifapentine and Isoniazid weekly for 12 weeks, Rifampin and Isoniazid daily for 12 weeks
- Where
- 21 sites in United States, Australia and 6 more
- Volunteers
- 3,400 people
- Sponsor
- Centers for Disease Control and Prevention
BCG Vaccination Reaction, Tuberculosis
A Study of GC3107(BCG Vaccine) in Healthy Infants
The purpose of this study is to investigate the efficacy and safety of GC3107 in healthy infants
- Trial name
- NCT03947138
- Testing
- GC3107, Intradermal BCG SSI inj.
- Where
- 2 sites in South Korea
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
HIV Infections, Tuberculosis
Efficacy of 400 mg Efavirenz Versus Standard 600 mg Dose in HIV/TB Co-infected Patients
TB is the most common cause of death in patients with HIV worldwide. Rifampicin [RIF] is the cornerstone of anti-TB therapy. Current guideline recommend efavirenz (EFV) 600mg per day as the first of choice for HIV/TB…
- Trial name
- NCT04513379
- Testing
- Efavirenz 600mg, Efavirenz 400mg
- Volunteers
- 80 people
- Sponsor
- Shanghai Public Health Clinical Center
Latent Tuberculosis
Video Based Directly Observed Therapy for Latent TB
Center for Disease Control (CDC) data reveal that after years of sustained decrease, the incidence of active tuberculosis (TB) disease in the US has plateaued.
- Trial name
- NCT03783728
- Testing
- Rifapentine 600 mg orally, Isoniazid 900 mg orally, Pyridoxine 50 mg orally
- Where
- United States
- Sponsor
- St. Louis University
Pulmonary Tuberculosis, Multidrug Resistant Tuberculosis
Linezolid to Treat Extensively-Drug Resistant Tuberculosis
This study, conducted in Masan and Seoul, South Korea, investigated the effectiveness of linezolid (LZD) in treating patients with extensively drug resistant tuberculosis (XDR TB).
- Conditions
- Pulmonary Tuberculosis, Multidrug Resistant Tuberculosis, Extensively Drug Resistant Tuberculosis
- Trial name
- NCT00727844
- Testing
- Immediate Start Linezolid, Delayed Start Linezolid
- Where
- 2 sites in South Korea
- Volunteers
- 41 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)